Literature DB >> 17640958

Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.

Andrew J Lickteig1, Craig D Fisher, Lisa M Augustine, Lauren M Aleksunes, David G Besselsen, Angela L Slitt, Jose E Manautou, Nathan J Cherrington.   

Abstract

Efflux transporters are responsible for the excretion of numerous xenobiotics and endobiotics and thus play an essential role in proper liver and kidney function. Nonalcoholic fatty liver diseases (NAFLDs) comprise a spectrum of disorders that range from simple fatty liver (SFL) to nonalcoholic steatohepatitis (NASH). Although the precise events leading to NAFLD are unclear, even less is known about the effects on efflux transporter expression and drug disposition. The purpose of this study was to determine the effect of NAFLD on efflux transporter expression in rat liver as well as on acetaminophen (APAP) metabolite excretion. To simulate SFL and NASH, rats were fed either a high-fat (HF) or a methionine- and choline-deficient (MCD) diet for 8 weeks. In the livers of MCD rats, there were striking increases in both mRNA and protein levels of multidrug resistance-associated protein (Mrp) 3, Mrp4, and breast cancer resistance protein, as well as increased Mrp2 protein. After administration of a nontoxic dose of APAP, biliary concentrations of APAP-sulfate, APAP-glucuronide (APAP-GLUC), and APAP-glutathione were reduced in MCD rats. The effects of the HF diet on both transporter expression and APAP disposition were by comparison far less dramatic than the MCD diet-induced alterations. Whereas APAP-sulfate levels were also decreased in MCD rat plasma, the levels of the Mrp3 substrate APAP-GLUC were elevated. Urinary elimination of APAP metabolites was identical between groups, except for APAP-GLUC, the concentration of which was 80% higher in MCD rats. These studies correlate increased hepatic Mrp3 protein in the MCD model of NASH with increased urinary elimination of APAP-GLUC. Furthermore, the proportional shift in elimination of APAP metabolites from bile to urine indicates that MCD-induced alterations in efflux transporter expression can affect the route of drug elimination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640958     DOI: 10.1124/dmd.107.015107

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

1.  Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression.

Authors:  Natsuko Tsuda; Osamu Matsui
Journal:  Eur Radiol       Date:  2011-08-11       Impact factor: 5.315

2.  Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Authors:  John D Clarke; Rhiannon N Hardwick; April D Lake; Mark J Canet; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2014-01-08       Impact factor: 4.030

Review 3.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

Review 4.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

5.  Regulation of hepatic phase II metabolism in pregnant mice.

Authors:  Xia Wen; Ajay C Donepudi; Paul E Thomas; Angela L Slitt; Roberta S King; Lauren M Aleksunes
Journal:  J Pharmacol Exp Ther       Date:  2012-10-10       Impact factor: 4.030

Review 6.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

7.  Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Matthew D Merrell; Rhiannon N Hardwick; Amy M Bataille; Sarah N Campion; Daniel W Ferreira; Stavra A Xanthakos; Jose E Manautou; H Hesham A-Kader; Robert P Erickson; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2015-03-18       Impact factor: 3.922

8.  Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Michael J Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-12-08       Impact factor: 3.922

9.  Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice.

Authors:  Maxwell Afari Gyamfi; Yuji Tanaka; Lin He; Curtis D Klaassen; Yu-Jui Yvonne Wan
Journal:  Toxicol Appl Pharmacol       Date:  2008-10-08       Impact factor: 4.219

10.  Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.

Authors:  Craig D Fisher; Andrew J Lickteig; Lisa M Augustine; Ronald P J Oude Elferink; David G Besselsen; Robert P Erickson; Nathan J Cherrington
Journal:  Eur J Pharmacol       Date:  2009-04-07       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.